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Background: Caspase-3 inhibition has been demonstrated to be therapeutically effective in moderating excessive
programmed cell death. Interest in caspase-3 as a therapeutic target has led many to pursue the development of
inhibitors. To date, only a few series of non-peptide inhibitors have been described, and these have limitations on
their drug-like properties.
Methods: Here, we report the screening of 70 novel small molecules against the caspase-3 enzyme which belongs
to four different series (indole fluoromethylketone, indole difluoro and tetrafluorophenoxymethylketone, and
oxalamide). Selected molecules were subjected for counter-screening, cell-based, ADME/PK assays in order to
understand the potency and drug-like properties.
Results: The screening yielded series of hits with IC50 values ranging from 0.11 to 10 μM with reasonable SAR,
irreversible mode of inhibition, and reasonable selectivity against other proteases including caspase-1, cathepsin B
and D, and thrombin. On the basis of in vitro profile, the selected molecules were evaluated for their drug-like
properties. Among the compounds evaluated, compound 3D exhibited good solubility, low permeability, interaction
with efflux pump, and low potential for CYP450 drug-drug interaction. After intravenous administration, compound
3D showed low clearance (588 ml/hr/kg), medium volume of distribution, and good oral bioavailability (90%).
Conclusions: These results support further advancement of compound 3D in different apoptotic models to develop
as a new anti-apoptotic agent in relevant disease conditions.
Keywords: Caspase-3, Small molecule, Apoptosis, InhibitionBackground
Apoptosis or programmed cell death is a critical cellular
process in normal development and homeostasis of multi-
cellular organisms. Cells undergo apoptosis in response to
a variety of stimuli, and during apoptosis, they do so in a
controlled, regulated fashion [1]. A major biochemical
pathway involved in the apoptosis includes a family of
proteases, known as caspases, which act in a cascade to
activate downstream caspases responsible for breakdown
or cleavage of key cellular substrates required for normal
cellular fashion, including structural proteins in the* Correspondence: samiulla_d@aurigene.com
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in any medium, provided the original work is pcytoskeleton and nuclear proteins such as DNA repair
enzymes [2,3].
Caspases are found practically in all organisms from
Caenorhabditis elegans to humans. At least 12 of the
caspases have been identified (caspases 1 through 10, 13,
and 14). Caspases share similarities in amino acid se-
quence, structure, and substrate specificity, and are
subdivided in to two subfamilies based on their func-
tionality: caspases involved in inflammation (caspases 1,
4, 5, 11, 12, 13, and 14) and apoptosis-related caspases
(caspases 2, 3, 6, 7, 8, 9, and 10). Among the identified
caspases, activation of caspase-3 is a key event integrat-
ing upstream signals into final execution of cell death [4].
Abnormally high amounts of apoptosis have been
reported in several liver diseases, including alcoholic
hepatitis, transplantation, Wilson's disease, and viralan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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ition of caspases protect the liver from apoptosis-
associated liver injury in preclinical models. Prototypical
caspase inhibitors such as ZVAD-FMK have been shown
to be efficacious in many animal models, including α-
Fas- and TNF-mediated liver injury [7]. More recently,
other caspase inhibitors have been shown to be effica-
cious in rodent models of liver disease [6] (Figure 1). Ef-
ficacy with the broad-spectrum caspase inhibitors in
preclinical models suggests that they have potential for
the treatment of liver diseases in humans. In addition,
procaspase-3 concentration is elevated in certain neuro-
blastomas, lymphomas, leukemias, melanomas, and liver
cancer [4]. This makes caspase-3 an interesting thera-
peutic target, and the search for caspase-3 inhibitors has
been an ongoing endeavor by many pharmaceutical
companies.
The objective of the present study is to characterize
novel small molecule caspase-3 inhibitors with an em-
phasis on understanding absorption, distribution, metab-
olism, and excretion (in vitro ADME), and in vivo
pharmacokinetic properties towards achieving desired





4-methylcoumarin (A1086), cathepsin B (C0150), Boc-
Gln-Ala-Arg-7-amido-4-methylcoumarin hydrochloride
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2,6-dimethylbenzoyl-oxymethyl ketone (A4339) were


















Figure 1 Structures of caspase-3 inhibitors in discovery and developmenzyme (BML-AK701) was from Enzo Life Sciences, Inc.
(NY, USA). Thrombin enzyme (HT1002a) was procured
from Enzyme Research Laboratories (IN, USA). Cathe-
psin B substrate (Z-Phe-Arg-AMC HCl) was from
Bachem AG (Bubendorf, Switzerland) (cat. no.: I-1160).
Cathepsin inhibitor II-ALLN (cat. no.: 219426) was from
Calbiochem AG (EMD Millipore Corporation, MA,
USA). All other reagents were of research grade.
IDN6556 was synthesized at Aurigene Discovery Tech-
nologies Ltd. (Karnataka, India). Selectivity against
caspase-7, 8, and 9, and cathepsin-D were performed
using Biomol kit (Enzo Life Sciences, Inc.).
General analytical methods
Fluorescence measurements were done using VIC-
TOR2V 96/384 multilabel plate reader (PerkinElmer Life
Sciences, MA, USA) at λex = 360 nm and λem = 460 nm
top readout (ex, excitation; em, emission) in Corning
black 96-well flat bottom plates. The enzyme activity
was measured at 30°C after 30 min. Trans-epithelial re-
sistance (TEER) measurements (for monolayer integrity)
were made using instrument from World Precision In-
strument (Florida, USA). HPLC (1100 series, Agilent
Technologies Inc., CA, USA) was performed on reverse
phase column (Zorbax Eclipse XDB C18, 150 × 4.6 mm,
5 μm). LC-MS/MS was performed in multiple reaction
monitoring mode using Applied Biosystems API 3200
(Chromos, Singapore) coupled to Agilent Technologies
1100 series HPLC on a reverse phase column (Zorbax
Eclipse XDB C18, 50 × 4.6 mm, 5 μm).
Compound selection and screening
Focused diversity approach was employed for the synthe-
sis of compounds at Aurigene Discovery TechnologiesMX-1013
VX-765
ent stage.
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[8,9]. As the active site of caspase-3 contains a sulfhydryl
moiety necessary for its catalytic activity, we focused on
molecules with the warheads (electrophilic moiety: car-
bonyl group of fluoromethylketone) capable of reacting
with the cysteinyl thiols. We selected 70 novel small
molecules (NCEs) with sufficient chemical diversity
belonging to four different series (indole fluoromethylke-
tone, indole difluoro and tetrafluorophenoxymethylke-
tone and oxalamide) and purity more than 95%.
Screening of compounds was carried out at two different
concentrations (1 and 10 μM). Selected compounds were
subjected to dose response determination in semi-log con-
centration (serial threefold dilutions) at constant DMSO
concentration of 1% with highest compound concentration
at 100 μM. Counterscreening against some of proteases,
permeability, and CYP450 inhibition studies was carried
out for few selected compounds at 10 μM concentration.
Protease inhibition assays
The ability of NCEs to inhibit the activity of human re-
combinant caspases as well as other proteases was deter-
mined using a standard fluorometric microplate assay as
described in [1,10]. The assay buffer contained 25 mM
sodium HEPES, 50 mM KCl, 0.1% CHAPS, and 1 mM
β-mercaptoethanol, pH7.4. To a reaction mixture (100
μL) containing the above buffer, 10 μM AC-DEVD-
AMC and 10 U caspase-3 were added in a black 96-well
microplate. Activities of the other caspases were deter-
mined similarly using the corresponding fluorogenic
substrates: 50 U of caspase-1 and 10 μM N-acetyl-Tyr
-Val-Ala-Asp-7-amido-4-methylcoumarin.
Thrombin assay reaction mixture (100 μl) contained
140 ng of enzyme and 100 μM of substrate (Boc-Glu-Ala-
Arg-AMC) in Tris–HCl buffer pH 8.5. Cathepsin-B assay
buffer contained 50 mM MES, 0.01% CHAPS, 100 μM of
substrate (Z-Phe-Arg-AMC HCl), and 0.1 U of enzyme.
The selectivity profile of 3D against caspase-7, 8, and 9, and
cathepsin-D was performed using Biomol kit (Enzo Life
Sciences, Inc.). The enzyme activities were monitored
(ex/em 355/460) as a time-course measurement of the in-
crease in fluorescence signal from fluorescently labeled pep-
tide substrate for 120 min at room temperature. Percent
inhibition calculation was calculated using following equa-
tion:
Percent inhibition ¼ 100
½ RFU in test wells=RFU in basal control wellsð Þ
100
Mechanistic analysis of caspase-3 inhibition
Thirty microliters of caspase-3 (200 U) in assay buffer
containing 30 μL of 20× NCE (the final compound con-
centration is approximately tenfold higher than respect-
ive IC50s). The mixture was incubated for 30 and 60 minat 30°C and then diluted 100-fold with assay buffer con-
taining 10 μM AC-DEVD-AMC. The enzyme activity
was measured at 30°C after 30 min. As a control, a mix-
ture of 1× caspase-3 and 1× NCE was prepared and
incubated for the same time duration before the addition
of the substrate.
Anti-apoptotic assay using Jurkat T-cells
The anti-apototic assay was done as described in [10].
Briefly, Jurkat (human T-cell leukemia) cell line (ATCC)
was cultured in RPMI-1640 medium with L-glutamine
and supplemented with 10% fetal bovine serum and anti-
biotic solution. Cells were grown at 37°C in 5% CO2 and
95% air environment at 100% humidity. Cells were pla-
ted in 45 μL/well of serum-free medium at 2.5 × 105
cells/mL and incubated for 1 h before compound
addition. Compound stock solutions were diluted with
growth medium and added to the cells to obtain desired
concentration. One percent DMSO was used for control
wells (without the addition of compounds). Cells were
incubated for 30 min before the addition of 5 μL of the
apoptosis-inducer staurosporine (final concentration of
100 nM). After 24 or 48 h of incubation, resazurin re-
agent was added at 5.5 μL/well. Cells were further incu-
bated for 120 min, and the fluorescence was measured
using the Wallac Victor2V plate reader (PerkinElmer
Life Sciences) at 531/589 nm ex/em wavelengths. The
percent protection from induced apoptosis was calcu-
lated using the following equation:
Percent protection ¼ ΔFlt  ΔFlsð Þ= ΔFln  ΔFlsð Þ
100;
where ΔFl denotes the difference in resazurin fluores-
cence measured at point 0 and after 120-min incubation
with the cells; subscripts t, s, and n are fluorescence in
the presence of a test compound + staurosporine, staur-
osporine alone, and no staurosporine, respectively.
ADME assays
Aqueous solubility
A high throughput kinetic solubility profiling was carried
out by shake flask method in 96-well format at pH 7.4
and 5.4 with theoretical test concentration of 200 μM.
After 16 h of incubation, the supernatant was subjected
for analysis.
Permeability
PAMPA assay was carried out using PION kit at 10-μM
test concentration according to the instructions provided
by the manufacturer. Permeability assay using Caco-2
cell monolayer.
Briefly, Caco-2 cells (ATCC) were grown in DMEM
supplemented with 10% fetal bovine serum, 1 mM non-
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tamicin sulfate (50 μg/ml) to 70% to 80% confluency
prior to seeding in 24-well plates loaded with polycar-
bonate Millicell inserts (12-mm diameter, 0.4 μm, 40,000
cells/insert; Millipore Co., MA, USA) at 37°C, 5% CO2
for 21 days. Cell monolayer integrity was assessed by
measuring TEER. Drugs were applied at 10 μM in
Hank's buffered salt solution to the apical or basal
chamber, and transport assay was carried out for 2 h at
37°C in presence and absence of cyclosporin A. At the
end of the assay, samples from both apical and basal
chambers were collected for analysis, and the monolayer
integrity was re-assessed by dye rejection using Lucifer
yellow. Apparent permeability (Papp) was calculated
using the equation:
Papp cm=secð Þ ¼ dQ=dt 1=Co  1=A;
where dQ/dt is the amount of drug transported within a
given time period (μmol/sec); C0 is the initial concentra-
tion in the donor solution (μM); A is the surface area of
insert filter membrane (cm2); and t is the incubation
time (sec).
Efflux ratio ERð Þ ¼ Papp B to A=Papp A to B;
where Papp B to A is the Papp value measured in the B to
A direction; Papp A to B is the Papp value measured in the
A to B direction. Note that efflux ratios greater than 2
(or 3) are generally considered to be evidence for trans-
port. Follow-up studies using inhibitors of drug trans-
porters (e.g., cyclosporin A) was done to develop further
evidence.
Microsomal stability
Mouse liver microsomes (in-house prepared) and pooled
human liver microsomes (BD Gentest, CA, USA) were
incubated with 1-μM test compounds at 37°C for 15 and
60 min using NADPH and UDPGA as co-factors. The
reaction was stopped by the addition of cold acetonitrile,
precipitated protein was removed, and the supernatants
were analyzed.
Cytochrome P450 inhibition
Human recombinant CYP450 isozymes 1A2, 2 C9, 2
C19, 2D6, and 3A4 (BD Gentest) were incubated with
10 μM of test compound in buffer containing 0.1%
DMSO for 10 min at 37°C, and the residual enzyme ac-
tivity was measured using fluorogenic substrates as per
BD Gentest protocol.
Animals
Animal experimental procedures used in this study were
approved by the Institutional Animal Ethical Committee
based on the Committee for the Purpose of Control andSupervision on Experiments on Animals guidelines.
Mice were used for the experiment after one-week
acclimatization to standard laboratory conditions. Mice
were fed with standard diet and water ad libitum.
In vivo pharmacokinetic experiment in mice
Pharmacokinetic profiling was carried out using oral and
intravenous route (IV) dosing in male NMRI mice. Three
animals per route were administered test substance
(1 mg/kg IV, 5 mg/kg PO) dissolved in vehicle containing
2% ethanol, 10% hydroxypropyl-β-cyclodextrin (HP-b-
CD) and/or 1% Poloxamer 188 and quantity sufficient
amount of 0.9% normal saline given at 10 ml/kg. The
plasma samples were collected at different time points
until 8 hr and were stored frozen at −80°C until analysis.
Quantitative bio-analysis of the drugs in the plasma sam-
ples was done using an LC-MS/MS. Plasma samples were
analyzed following protein precipitation of plasma with
acetonitrile containing internal standards.
Data fitting and statistical analysis
Curve fitting was performed with Prism 5.1 software
(GraphPad Software Inc., San Diego, CA) using built-in
equation describing corresponding data models. All the
other data were mentioned as mean ± standard devi-
ation of triplicates values. PK parameters were deter-
mined using WinNonlin 5.2 software.
Results and discussion
Biochemical screening
For screening of the compound library, the caspase-3
biochemical assay was first optimized. The fluorescence
signal as well as signal to noise ratio was optimal at 10
U of caspase-3 and 10-μM substrate. Substrate exhibited
Michaelis-Menten constant of 11.7 μM and was compar-
able to the published data [10]. The caspase-3 assay was
validated using reference inhibitor (IDN6556) across all
plates and different experiments [10-12].
The primary screen of the 70 compounds at concen-
tration of 1 and 10 μM revealed 22 hits (higher than
50% inhibition threshold at 10 μM) with dose-dependent
inhibition (data not shown). The hits belong to all the
four series, and most potent molecule is from indole
chemotype, a chemotype previously reported to show
good inhibition of cysteine proteases [4]. There was a
clear trend in dose dependent inhibition of caspase-3 ac-
tivity for all tested compounds from all four chemotypes
(Figure 2A). It was observed that fluoromethylketone as
a warhead is more potent than other substitutions like
oxalamide. More bulky lipophilic groups substantially
reduced the potency, and more polar and hydrophilic
groups increased the potency. Electrophilic carbonyl
from fluoromethylketone group might serve as sites of
nucleophilic attack by cysteine thiolates in the caspase-3
A 


















Target IC50 (µM) Fold selectivity
Caspase 3 0.11 -
Caspase 7 0.197 1.8
Caspase 8 0.182 1.7
Caspase 9 0.067 0.6
Caspase 1 >10 >100
Cathepsin D >10 >100
Cathepsin B >10 >100
Thrombin >10 >100
Figure 2 Concentration-dependent inhibition and selectivity profile of NCEs. (A) Concentration-dependent inhibition of caspase-3 with
NCEs measured in presence of substrate (AC-DEVD-AMC) at 10 μM. The percentage of inhibition was calculated relative to the enzyme activity
with no inhibitor present. (B) Selectivity profile of 3D using Biomol kit (Enzo Life Sciences, Inc.). The enzyme activities were monitored (ex/em
355/460) as a time-course measurement of the increase in fluorescence signal from fluorescently labeled peptide substrate for 120 min at room
temperature.
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characterized in the follow-up mechanistic assays, coun-
terscreening assays against other proteases including
caspase-1, 3, 7, 8, and 9, cathepsin-B and D, and
thrombin.
Time-dependent inhibition of caspase-3 activity
Reversibility assessment of the caspase-3 activity with
selected compounds was determined in the dilution ex-
periment as described in the ‘Methods’ section. From
the data shown in Figure 3, time-dependent inhibition of
caspase-3 activity suggests irreversible interaction ofFigure 3 Time-dependent inhibition of caspase-3 activity with NCEs. C
was pre-incubated with 20× NCE (the final compound concentration is app
pre-incubated for 30 and 60 min at 30°C and then diluted 100-folds with a
measured at 30°C after 30 min. As a control, a mixture of 1× caspase-3 and
before addition of the substrate. The percentage inhibition was calculated
procedures for concentrated or control samples but without the inhibitor.
oxalamide series.compounds with caspase-3 enzyme and is similar to the
reported caspase inhibitor IDN6556 [6,10,13].
Counterscreen profile
The selectivity profile of selected compounds was
assessed using a panel of proteases including cysteine
proteases. The substrate concentration as well as other
reaction conditions used for each assay is described in
the ‘Methods’ section. The selectivity studies (refer to
Figure 2B) indicated that compound 3D was not select-
ive towards caspases 7, 8, and 9 but good selectivityaspase-3 at a 20× concentration, as specified in the ‘Methods’ section,
roximately tenfold higher than respective IC50s). The mixture was
ssay buffer containing 10-μM AC-DEVD-AMC. The enzyme activity was
1× NCE was prepared and incubated for the same time duration
relative to the activity of caspase-3, which went through all the
Note that compounds 1A to 3E are from indole, and 4A to 4F from
Samiulla et al. Organic and Medicinal Chemistry Letters 2012, 2:27 Page 6 of 7
http://www.orgmedchemlett.com/content/2/1/27(>100-fold) over proteases including caspase-1, throm-
bin, cathepsin-B, and cathepsin D.
Evaluation of anti-apoptotic activity
Protection against cellular apoptosis was determined
using staurosporine as apoptotic inducer in Jurkat cells
(human T-cell leukemia), as described in the ‘Methods’
section. Apoptosis in cells was measured as the suppres-
sion of resazurin reduction rate after 48-h incubation
with staurosporine and in the presence and absence of
compounds. Most of the compounds, with the exception
of compound 3D, showed minimal protection or no ef-
fect on staurosporine-induced apoptosis likely due to
low permeability as observed in PAMPA assay (data not
shown).
Evaluation of compounds in in vitro ADME assay panel
The ADME profile for the selected set of compounds
was determined using standard battery of assays includ-
ing aqueous apparent solubility, microsomal metabolic
stability, Caco-2 permeability, and drug-drug interaction
studies using recombinant CYP450 enzymes. It is
observed that the presence of polar group (such as acidic
moiety) may help in good solubility and lack of transport
of compound across the cell membrane in order to
reach the target. Substitution of tetrafluorophenoxy
showed interaction with efflux pump. Most of the com-
pounds from fluoromethyl substitution on indole moiety
and oxalamide showed relatively high microsomal stabil-
ity compare to other substitutions. The optimal micro-
somal stability was found with substitution (Cl or OMe)
on 5th position of indole with either difluoro and tetra-
fluorophenoxymethylketone substitution [see Table S1B
in Additional file 1].
Inhibition of cytochrome P450 (CYP450) drug metab-
olizing enzymes may alter the metabolism of co-adminis-
tered compounds, leading to a change in exposure and
possible toxicity. Thus, the potential for the drug-drug
interaction of NCEs was assessed by monitoring their im-
pact on the metabolic activity of a panel of five major
human CYP450 isoforms (3A4, 2 C9, 2 C19, 2D6, and
1A2) in the presence of a known fluorescent substrate
for each of the isoform. CYP3A4 inhibition was deter-
mined in three assays using three distinct fluorescent
substrates to account for the existence of two substrate
binding sites. The results of these six assays are reported
in Table S3 in Additional file 1. All the tested compounds
showed no significant CYP450 inhibition under tested
conditions, indicating no major alerts in drug-drug
interactions.
Pharmacokinetic profile of compounds in rodents
Compounds were administered to male NMRI mice ei-
ther as 1 mg/kg intravenous bolus in 1% (v/v) DMA,10% (w/v) HP-b-CD in normal saline, or orally by gavage
at 5 mg/kg in 1% (v/v) DMA, 1% (w/v) Poloxamer 147,
and 10% (w/v) HP-b-CD in saline. The relevant pharma-
cokinetic parameters reported in Table S4 in Additional
file 1 indicate that the oral bioavailability of compound
3D (having tetrafluoro substitution) in this study was
90%, which was more when compared other compounds
(such as series 1 and 4). A relatively high volume of dis-
tribution observed after IV dosing indicates that the
compound gets distributed rapidly from the vascular
compartment into the peripheral tissues. The plasma
clearance was high (greater than hepatic blood flow) for
most of the compounds tested except for compound 3D
with clearance value of 588 ml/h/kg (15% of hepatic
blood flow).
Caspases play an important role in different patho-
physiological conditions, and specific inhibition is
expected to be therapeutically valuable. Towards identi-
fying novel inhibitors of caspases with desirable selectiv-
ity, ADME and efficacy profile, we screened a focused
library of compounds and identified inhibitors from four
chemical series that are distinct from other known small
molecule caspase-3 inhibitors. Among the hits identified
with potency ranging from 0.11 to 50 μM IC50, com-
pounds from two series that displayed potent caspase-3
inhibition were analyzed for reversibility. All the tested
compounds from four series were found to be highly ir-
reversible for their inhibition of caspase activity.
Caspase-3 possess a total of seven cysteinyls, out of
which three (excluding one in the active site) are readily
accessible to water and, hence, to potential oxidation. It
is well known in the literature that the compounds with
warhead possess the irreversible type of caspase inhib-
ition [13].
ADME properties including the permeability of the
compounds with an objective of selecting the com-
pounds with greater potential for cellular activity were
analyzed. Although permeability of all the tested com-
pounds were low, modest cellular activity suggested that
compounds 3D and 1D were more potent than other
compounds and may be because of marginally better
permeability. Halogen (Cl) substitution on 5th position
along with tetrafluorophenoxymethylketone substituent
on right-hand side of molecule (as in compound 3D)
resulted in greater stability in liver microsomes [see
Table S1A in Additional file 1] and higher interaction
with efflux pump as indicated by higher efflux ratio in
the Caco-2 permeability assays [see Table S3 in
Additional file 1]. It also shows advantages in lowering
the plasma clearance to about 10% of hepatic blood flow
and increase in the oral bioavailability, which led to a good
oral exposure. The interesting in vitro as well in vivo pro-
file of compound 3D supports further evaluation in effi-
cacy models. However, such potential advantages need to
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3D in different pharmacological studies as well as in vivo
toxicity evaluation.Conclusions
In summary, this study supports the hypothesis that cas-
pase inhibition may protect cells from abnormal amount
of apoptosis seen in a number of disease states. Contin-
ual treatment with a caspase inhibitor may preserve the
loss of critical numbers of cells responsible for the devel-
opment of caspase-mediated cell death. These results
support further analysis of compound 3D as a potential
anti-apoptotic agent in pre-clinical models of apoptosis.Additional file
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pharmacokinetic properties of NCEs. Description: Table S1 (A and B),
structure-activity relationship analysis of hits around chemotype I, II and
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